Four major polymeric architectures, namely: (a) linear, (b) branched, (c) hyperbranched/dendritic and (d) cross-linked polymers, when formed by reaction of multifunctional alcohols, such as sugar-based alpha-, beta- or gamma-cyclodextrins, with multi-carboxylic acids form unique polyester copolymers. These copolymers have been demonstrated to substantially enhance the water-solubility and bioavailability of water insoluble compounds for a wide variety of uses.

Four major polymeric architectures, namely: (a) linear, (b) branched, (c) hyperbranched/dendritic and (d) cross-linked polymers, when formed by reaction of multifunctional alcohols, such as sugar-based alpha-, beta- or gamma-cyclodextrins, with multi-carboxylic acids form unique polyester copolymers. These copolymers have been demonstrated to substantially enhance the water-solubility and bioavailability of water insoluble compounds for a wide variety of uses.

The present disclosure encompasses pharmaceutical composition, kits and methods for enhancing therapeutic compliance.

The present disclosure encompasses pharmaceutical composition, kits and methods for enhancing therapeutic compliance.

The present invention relates to a pharmaceutical formulation of siponimod which can be administered parenterally. In particular, the present invention relates to a parenteral solution comprising siponimod and a method for preparing said solution.

The present invention provides compositions or formulations comprising the combination of a compound of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione or a salt thereof or hydrate of the foregoing, and a cyclodextrin; or in further combination with an excipient comprising L-Arginine or other additives, wherein the compositions or formulations increases water solubility and oral bioavailability of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and its related compounds. The method of making or using the compositions or formulations is also disclosed. Such compositions or formulations may be used in treatment of certain diseases including asthma through inhibition of matrix metalloproteinase-12.

The present invention provides compositions or formulations comprising the combination of a compound of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione or a salt thereof or hydrate of the foregoing, and a cyclodextrin; or in further combination with an excipient comprising L-Arginine or other additives, wherein the compositions or formulations increases water solubility and oral bioavailability of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and its related compounds. The method of making or using the compositions or formulations is also disclosed. Such compositions or formulations may be used in treatment of certain diseases including asthma through inhibition of matrix metalloproteinase-12.

Disclosed herein are pharmaceutical compositions, formulations, and dosage forms and their use in the treatment of a cancer. Also disclosed herein are methods of treating a cancer in a subject in need thereof.

A beverage composition promotes cellular hydration when ingested by a multicellular organism, and includes a carbohydrate clathrate component that includes cyclodextrin, in a concentration of 0.01-5% w/w. A complex-forming compound is also included in a concentration that is less than the clathrate component, and there is an aqueous liquid component, such as still and carbonated aqueous liquids. An inclusion complex is formed with at least some of the clathrate component and at least some of the complex-forming compound and the composition promotes cellular hydration of the multicellular organism when the multicellular organism ingests it. There is also a beverage composition that increases lifespan in the multicellular organism, and methods of promoting cellular hydration and increasing lifespan of the multicellular organism according to a mechanism of action.

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.